Bioequivalence Study of Ondansetron Orally Disintegrating Tablets 8mg Under Fed Conditions
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the single-dose oral bioavailability of Ondansetron 8
mg orally disintegrating tablets of Ohm Laboratories (A subsidiary of Ranbaxy
Pharmaceuticals, USA) with Zofran ODT® 8 mg orally disintegrating tablets of Cardinal health,
UK for GlaxoSmithKline, USA in healthy, adult, human, male subjects under fed condition.